Idorsia raises Sfr600m to fund drug commercialisation

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity-Linked

Idorsia raises Sfr600m to fund drug commercialisation

Aidan Gregory
July 28, 2021 04:00 pm
Idorsia_alamy_575_375
2CHEH7K Jean-Paul Clozel, CEO of Swiss pharmaceutical company Idorsia, gestures during an interview with Reuters at the company's headquarters in Allschwil near Basel, Switzerland May 15, 2018. Picture taken May 15, 2018. REUTERS/Arnd Wiegmann | Alamy Stock Photo

Idorsia, the Swiss biotech company, has turned to the convertible bond market to finance looming product launches and the development of its late-stage drug pipeline.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

SwitzerlandCredit SuisseHealth and BiotechEquityEuropeEMEASRIGoldman SachsEquity-Linked
AG
Aidan Gregory
Gift this article